Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,489
archived clinical trials in
Endometrial Cancer

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison Medical Center
mi
from
Bremerton, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison Medical Center
mi
from
Bremerton, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Skagit Valley Hospital Regional Cancer Care Center
mi
from
Mount Vernon, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Skagit Valley Hospital Regional Cancer Care Center
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Pacific Gynecology Specialists
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Northwest Hospital
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Washington Medical Center
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Olympic Medical Cancer Care Center
mi
from
Sequim, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Olympic Medical Cancer Care Center
mi
from
Sequim, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Saint Joseph Medical Center
mi
from
Tacoma, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Saint Joseph Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer
Status: Enrolling
Updated:  5/10/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer
Status: Enrolling
Updated: 5/10/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated:  6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated: 6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated:  6/1/2016
Washington University in St Louis (Siteman Cancer Center)
mi
from
St. Louis, MO
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated: 6/1/2016
Washington University in St Louis (Siteman Cancer Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated:  6/1/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated: 6/1/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Status: Enrolling
Updated:  12/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Status: Enrolling
Updated: 12/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Status: Enrolling
Updated:  12/14/2016
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
Status: Enrolling
Updated: 12/14/2016
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated:  4/24/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated: 4/24/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated:  4/24/2017
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Status: Enrolling
Updated: 4/24/2017
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lymphedema in Endometrial Cancer
A Pilot Study of Postoperative Lower-extremity Lymphedema and Quality of Life Among Women Undergoing Endometrial Cancer Staging Surgery
Status: Enrolling
Updated:  6/22/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Lymphedema in Endometrial Cancer
A Pilot Study of Postoperative Lower-extremity Lymphedema and Quality of Life Among Women Undergoing Endometrial Cancer Staging Surgery
Status: Enrolling
Updated: 6/22/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
The Hartford Hospital
mi
from
Hartford, CT
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated:  8/23/2017
Women and Infants Hospital
mi
from
Providence, RI
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Status: Enrolling
Updated: 8/23/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers
Status: Enrolling
Updated:  8/29/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers
Status: Enrolling
Updated: 8/29/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Hurley Medical Center
mi
from
Flint, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Pacific Gynecology Specialists
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Click here to add this to my saved trials